Active, not recruitingPhase 3NCT04881825

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

Studying Short bowel syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Zealand Pharma
Principal Investigator: Zealand Pharma
Zealand Pharma
Intervention: Glepaglutide(drug)
Enrollment: 129 enrolled
Eligibility: 18-90 years · All sexes
Timeline: 2021 – 2026

Study locations (19)

Georgetown University Medical Center, Washington D.C., District of Columbia, United States
Mayo Clinic College of Medicin, Rochester, Minnesota, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
Vanderbilt University Medical Center, Nashville, Nashville, Tennessee, United States
Universitair Ziekenhuis Leuven, Leuven, Belgium
Rigshospitalet, Copenhagen, Denmark
Hôpital Beaujon, Clichy, France
Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
Charité - Universitätsmedizin Berlin, Berlin, Germany
Universitätsklinikum Bonn, Bonn, Germany
Universitätsklinikum Frankfurt, Frankfurt, Germany
Asklepios Kliniken Hamburg GmbH, Hamburg, Germany
Universitätsmedizin Rostock, Rostock, Germany
UMC Radboud Nijmegen, Nijmegen, Netherlands
Wojewodzki Specjalistyczny Szpital im. M. Pirogowa w Lodzi, Lodz, Poland
+4 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04881825 on ClinicalTrials.gov

Other trials for Short bowel syndrome

Additional recruiting or active studies for the same condition.

See all trials for Short bowel syndrome →

← Back to all trials